Prospective Open-label Evaluation of Cenobamate Adjunctive Treatment of Adults With Refractory Focal Epilepsy

Focal Epilepsy Clinical Trial

Official title:

Prospective Open Label Evaluation of Cenobamate Adjunctive Treatment of Adults With Refractory Focal Epilepsy: a "Real-world Experience" Study.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04879433
• Other study ID #: maesc010
• Status: Recruiting
• Start date: June 25, 2020
• Est. completion date: November 30, 2023

Study information

• Verified date: August 2022
• Source: Mid-Atlantic Epilepsy and Sleep Center, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To evaluate the efficacy, safety and tolerability of cenobamate as adjunctive treatment of refractory focal epilepsy

Description:

The purpose of the study is to evaluate efficacy and safety of adjunctive cenobamate treatment of adults with drug-resistant focal epilepsy in "real world" clinical setting, providing "real world experience" to help guide future cenobamate treatment. This will be an open label study comparing seizure frequency during 52 weeks of baseline observation period with seizure frequency during 52 weeks of adjunctive cenobamate maintanance treatment. ~100 adults aged 18-70 with severe refractory focal epilepsy with focal seizures that have failed to respond to ≥ 4 antiseizure drugs (ASDs) +/- respective surgery +/- vagal nerve stimulator (VNS), responsive nerve stimulator (RNS) or deep brain stimulator (DBS) treatment with epilepsy duration of ≥ 2 years and followed by the Investigator and/or his epileptologist colleagues at the Investigator's institution for ≥ 1 year will be enrolled. Patients will be on ASDs deemed by the Investigator to have achieved the best seizure control to-date. No more than 5 ASDs will be used. VNS, RNS and DBS will be allowed and not counted as an ASD. However, patients on VNS, RNS or DBS will have to have had the device placed ≥ 6 months before study initiation and have had stable stimulator settings for ≥ 3 months. Baseline will include 52 weeks of prospectively kept, well documented seizure diaries that have been regularly, prospectively reviewed by the treating epileptologist during 52 weeks prior to study initiation. Retrospective review of these diaries will be allowed and count as baseline. As an alternative to seizure diaries, well-documented seizure frequency obtained during regular clinical visits, reviewed by the treating epileptologist and documented in the patient's chart during regular clinical visits during the 52 weeks' baseline period will be allowed in lieu of seizure diaries. ASDs will be held stable during the last month of baseline observation period. Following a baseline of 52 weeks patients will be started on cenobamate, administered orally in qhs, qd or b.i.d. schedule. Both starting dose and titration schedule up to initial target dose of 100-250 mg will follow FDA approved guidelines.

Cenobamate target dose will range from 100-400 mg/day. Within this range, the target dose will be individualized and will be the dose when seizure freedom, intolerable TEAEs or 400 mg/day is reached, whichever occurs first Maintenance period will start when seizure freedom, 250 mg/day dose or maximum tolerated dose of ≥ 100 mg/day is reached, whichever comes first. Maintenance treatment will last for 52 weeks. Total treatment period may vary between subjects depending on titration and final dose, but maintenance treatment period will be 52 weeks for all subjects. During both titration and cenobamate treatment, reduction of the dose of concomitant other ASDs will be allowed as clinically indicated; increase in the dose of concomitant ASDs will not be allowed, nor will initiation of any new antiseizure therapy other than cenobamate. Initiation of new antiseizure treatment or clinically indicated need for increase of ASD other than cenobamate will end of the active part of the study, although patients will be followed to the end of the 52 week maintenance treatment period.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: November 30, 2023
• Est. primary completion date: June 25, 2023
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Age 18-70

2. Focal epilepsy uncontrolled in spite of past or present treatment with four or more anti-seizure drugs (ASDs), with focal aware motor seizures, focal unaware seizures and focal to bilateral tonic clonic seizures.

3. Stable ASD doses for at least 30 days

4. Epilepsy duration for = 2 years

5. Past/current treatment with = 4 ASDs. VNS, RNS and DBS treatment will be allowed and will not count as an ASD. VNS, RNS and DBS setting must be stable for 3 months prior to enrollment.

6. Seizure frequency of =1/month for = 10/12 months before treatment initiation

Exclusion Criteria:

1. Primary generalized epilepsy

2. Focal aware non-motor seizures without bilateral tonic-clonic seizures

3. Non-epileptic seizures

4. Progressive neurological disease including neoplasm, CNS degenerative disorders including Alzheimer's disease

5. Any systemic illness or unstable medical condition that might pose additional risk, including renal or liver disease, clinically uncontrolled cardiac disease other unstable metabolic or endocrine disturbances, and active systemic cancer

6. Change in the dose of any ASD within 30 days prior to enrollment

7. Active drug or alcohol dependence or any other factors that, in the opinion of the site investigators would interfere with adherence to study requirements

8. Pregnancy

9. Use of any CNS-active investigational drugs within 1 month of enrollment

10. Resective epilepsy surgery less than 6 months before study initiation

11. Vagal nerve stimulator VNS, RNS or DBS implantation less than 6 months before study initiation

12. Adjustment of VNS, RNS or DBS settings less than 3 months before study initiation

13. Inability or unwillingness of subject or legal guardian/representative to give written informed consent.

Related Conditions & MeSH terms

• Epilepsies, Partial
• Epilepsy
• Focal Epilepsy

Locations

Country	Name	City	State
United States	Mid-Atlantic Epilepsy and Sleep Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Mid-Atlantic Epilepsy and Sleep Center, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The seizure frequency per 28 days.	comparing seizure frequency per 28 day periods during maintanance treatment vs. baseline	seizure count per 28 days, baseline 52 weeks, maintanance period 52 weeks
Primary	seizure freedom rate	rate of seizure-free patients	52 weeks of adjunctive cenobamate maintanance treatment
Primary	>75% seizure frequency reduction	rate of patients with >75% seizure frequency reduction, comparing seizure frequency per 28 day periods during maintanance treatment vs. baseline	seizure count per 28 days, baseline 52 weeks, maintanance period 52 weeks
Primary	treatment emergent adverse events rate	rate of treatment emergent adverse events	52 weeks of baseline period; whole treatment period
Primary	treatment discontinuation rate	rate of cenobamate treatment discontinuation	52 weeks of baseline period; whole treatment period
Secondary	median seizure frequency reduction	median seizure frequency reduction evaluation in maintenance period	52 weeks of baseline period; 52 weeks of adjunctive cenobamate maintanance treatment
Secondary	median seizure frequency reduction	median seizure frequency reduction evaluation in treatment period	52 weeks of baseline period; the whole treatment period
Secondary	seizure severity	evaluate a seizure severity composite score	52 weeks of baseline period; 52 weeks of adjunctive cenobamate maintanance treatment
Secondary	quality of life change	quality of life questionnaire (QOLIE-31-P) scores	52 weeks of baseline period; the whole treatment period
Secondary	seizure-related injuries	seizure-related injuries rate	52 weeks of baseline period; the whole treatment period
Secondary	driving status	rate of patients with changed driving status	52 weeks of baseline period; the whole treatment period